US Patent 11414494 Anti-GITR antibodies and uses thereof
Patent 11414494 was granted and assigned to Regeneron Pharmaceuticals on August, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 19 Oct, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 24 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
114144940
Date of Patent
August 16, 2022
0Patent Application Number
169139630
Date Filed
June 26, 2020
0Patent Primary Examiner
Edits on 25 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
114144940
Date of Patent
August 16, 2022
0Patent Application Number
169139630
Date Filed
June 26, 2020
0Patent Primary Examiner
Edits on 17 Aug, 2022
Golden AI
Edits made to:
Infobox (+14 properties)
Article (+238 characters)
US Patent 11414494 Anti-GITR antibodies and uses thereof
Article
Provided herein are antibodies, and antigen-binding fragments thereof that specifically bind glucocorticoid-induced tumor necrosis factor receptor (GITR) and methods of using the same, including, e.g., methods of treatment using the same.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
11414494
Date of Patent
August 16, 2022
Patent Application Number
16913963
Date Filed
June 26, 2020
Patent Primary Examiner
Find more entities like US Patent 11414494 Anti-GITR antibodies and uses thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
